ABD - İngilizce - NLM (National Library of Medicine)

akorn - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate lotion, 0.05% is a super-high potent topical corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older. treatment should be limited to 2 consecutive weeks. for moderate to severe plaque psoriasis, treatment may be extended for an additional 2 weeks for localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2-week treatment. any additional benefits of extending treatment should be weighed against the risk of hypothalamic-pituitary-adrenal (hpa) axis suppression before prescribing for more than 2 weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz) per week. patients should be instructed to use clobetasol propionate lotion, 0.05% for the minimum amount of time necessary to achieve the desired results [see dosage and administration (2) ]. use in patients under 18 years of age is not recommended due to

ABD - İngilizce - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. none. there are no available data on clobetasol propionate foam use in pregnant women to inform of a drug-associated risk for adverse developmental outcomes. published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparison of animal exposure w

ABD - İngilizce - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older. none. there are no available data on clobetasol propionate foam use in pregnant women to inform of a drug associated risk for adverse developmental outcomes. published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparison of animal exposure with human exposure was computed. the background risk of major birth defects and miscarriage for

ABD - İngilizce - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. none. risk summary there are no available data on clobetasol propionate foam use in pregnant women to inform of a drug-associated risk for adverse developmental outcomes. published data report a significantly increased risk of low birth weight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparison of ani

ABD - İngilizce - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate spray, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (bsa) in patients 18 years of age or older. patients should be instructed to use clobetasol propionate spray, 0.05% for the minimum amount of time necessary to achieve the desired results [see dosage and administration (2)] . use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of hpa axis suppression were seen with other clobetasol propionate topical formulations. [see use in specific populations (8.4)]. clobetasol propionate spray, 0.05% should not be used on the face, axillae, or groin. clobetasol propionate spray, 0.05% should not be used if there is atrophy at the treatment site. clobetasol propionate spray, 0.05% should not be used in the treatment of rosacea or perioral dermatitis. none. risk summary there are no available data on

ABD - İngilizce - NLM (National Library of Medicine)

remedyrepack inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate lotion, 0.05% is a super-high potent topical corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older. treatment should be limited to 2 consecutive weeks. for moderate to severe plaque psoriasis, treatment may be extended for an additional 2 weeks for localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2-week treatment. any additional benefits of extending treatment should be weighed against the risk of hypothalamic-pituitary-adrenal (hpa) axis suppression before prescribing for more than 2 weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz) per week. patients should be instructed to use clobetasol propionate lotion, 0.05% for the minimum amount of time necessary to achieve the desired results [ see dosage and administration (2) ]. use in patients under 18 years

ABD - İngilizce - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. none. risk summary there are no available data on clobetasol propionate foam use in pregnant women to inform of a drug-associated risk for adverse developmental outcomes. published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparison of animal exposure with human exposure was computed. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data human data multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. however, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants [adjusted rr, 7.74 (95% ci, 1.49 to 40.11)]. in addition, a small cohort study, in which 28 sub-saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. the majority of exposed subjects treated large areas of the body (a mean quantity of 60 g/month (range, 12 to170 g) over long periods of time. animal data embryofetal development studies conducted with clobetasol propionate in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and malformations at all dose levels tested down to 0.03 mg/kg. malformations seen included cleft palate and skeletal abnormalities. in an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg. malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities. risk summary there is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clobetasol propionate foam and any potential adverse effects on the breastfed infant from clobetasol propionate foam or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply clobetasol propionate foam directly to the nipple and areola to avoid direct infant exposure. safety and effectiveness of clobetasol propionate foam in patients younger than 12 years of age have not been established; therefore, use in children younger than 12 years is not recommended. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity when they are treated with topical drugs. they are, therefore, also at greater risk of adrenal insufficiency upon the use of topical corticosteroids. rare systemic toxicities such as cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients especially those with prolonged exposure to large doses of high potency topical corticosteroids. local adverse reactions including striae have also been reported with use of topical corticosteroids in pediatric patients. avoid use of clobetasol propionate foam in the treatment of diaper dermatitis. clinical studies of clobetasol propionate foam did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate shampoo, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. treatment should be limited to 4 consecutive weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz.) per week. patients should be instructed to use clobetasol propionate shampoo, 0.05% for the minimum time period necessary to achieve the desired results [see dosage and administration (2)] . use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (hpa) axis suppression [see warnings and precautions (5.1) and use in specific populations (8.4)] . clobetasol propionate shampoo, 0.05% should not be used on the face, groin or axillae. avoid any contact of the drug product with the eyes and lips. in case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo. none there are no adequate and well-controlled studies in pregnant women. therefore, clobetasol propionate shampoo, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. clobetasol propionate is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and the mouse. clobetasol propionate has greater teratogenic potential than steroids that are less potent. the effect of clobetasol propionate on pregnancy outcome and development of offspring was studied in the rat. clobetasol propionate was administered subcutaneously to female rats twice daily (0, 12.5, 25, and 50 μg/kg/day) from day 7 of presumed gestation through day 25 of lactation or day 24 presumed gestation for those rats that did not deliver a litter. the maternal no-observed-effect-level (noel) for clobetasol propionate was less than 12.5 μg/kg/day due to reduced body weight gain and feed consumption during the gestation period. the reproductive noel in the dams was 25 μg/kg/day (ratio of animal dose to proposed human dose of 0.07 on a mg/m2 /day basis) based on prolonged delivery at a higher dose level. the no-observed-adverse-effect-level (noael) for viability and growth in the offspring was 12.5 μg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2 /day basis) based on incidence of stillbirths, reductions in pup body weights on days 1 and 7 of lactation, increased pup mortality, increases in the incidence of umbilical hernia, and increases in the incidence of pups with cysts on the kidney at higher dose levels during the preweaning period. the weights of the epididymides and testes were significantly reduced at higher dosages. despite these changes, there were no effects on the mating and fertility of the offspring. systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. because many drugs are excreted in human milk, caution should be exercised when clobetasol propionate shampoo, 0.05% is administered to a nursing woman. use of clobetasol propionate shampoo, 0.05% in patients under 18 years old is not recommended due to potential for hpa axis suppression [see warnings and precautions (5.1) ] the effect of clobetasol propionate shampoo, 0.05% on hpa axis suppression was evaluated in one trial in adolescents 12 to 17 years of age with moderate to severe scalp psoriasis with involvement of at least 25% of the scalp. in this trial, 5 of 12 evaluable subjects developed suppression of their hpa axis following 4 weeks of treatment with clobetasol propionate shampoo, 0.05%, applied once daily for 15 minutes to a dry scalp before lathering and rinsing. only 1 of the 5 subjects who had suppression was tested for recovery of hpa axis, and this subject recovered after 2 weeks. no studies have been performed in patients under the age of 12. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression and cushing’s syndrome when they are treated with topical corticosteroids. they are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. therefore, use is not recommended in patients under the age of 18. hpa axis suppression, cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. clinical studies of clobetasol propionate shampoo, 0.05% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. in general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. instructions for use clobetasol propionate shampoo, 0.05% important: for use on the scalp only. do not get clobetasol propionate shampoo, 0.05% near or in your eyes, mouth or vagina. read the instructions for use that comes with clobetasol propionate shampoo, 0.05% before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or your treatment. how to apply clobetasol propionate shampoo, 0.05% to your scalp: your hair should be dry when you apply clobetasol propionate shampoo, 0.05% to your scalp. do not get clobetasol propionate shampoo, 0.05% on your face, in your eyes or on your lips. if clobetasol propionate shampoo, 0.05% does get on these areas, rinse well with water. step 1: to apply clobetasol propionate shampoo, 0.05% to your scalp, part your hair at the area where it is to be applied. step 2: hold the bottle of clobetasol propionate shampoo, 0.05% over the affected area. gently squeeze the bottle and apply a small amount of shampoo to the affected area. step 3: gently rub clobetasol propionate shampoo, 0.05% into the affected area so that only the affected area is covered with a thin, even layer of clobetasol propionate shampoo, 0.05%. step 4: repeat steps 1 through 3 to apply clobetasol propionate shampoo, 0.05% to other affected areas on your scalp as instructed by your doctor. step 5: wash your hands after applying clobetasol propionate shampoo, 0.05%. step 6: leave clobetasol propionate shampoo, 0.05% on your scalp for 15 minutes. you should not bandage or cover your head with a shower cap, bathing cap, or a towel while clobetasol propionate shampoo, 0.05% is on your scalp, unless your doctor tells you to. step 7: after 15 minutes have passed, wet your hair with water. lather and rinse your hair and scalp completely. rinse any other parts of your body that come into contact with clobetasol propionate shampoo, 0.05%, such as your hands, face, neck and shoulders. no other shampoo is needed, but you may wash your hair with a non-medicated shampoo after using clobetasol propionate shampoo, 0.05%. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by padagis yeruham, israel distributed by padagis, allegan, mi 49010 • www.padagis.com rev 06-22

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate foam, 0.05% is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. none. risk summary there are no available data on clobetasol propionate foam, 0.05% use in pregnant women to inform of a drug-associated risk for adverse developmental outcomes. published data report a significantly increased risk of low birth weight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam, 0.05% on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparison of animal exposure with human exposure was computed. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data human data multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. however, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants [adjusted rr, 7.74 (95% ci, 1.49–40.11)]. in addition, a small cohort study, in which 28 sub-saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. the majority of exposed subjects treated large areas of the body (a mean quantity of 60 g/month [range, 12–170g]) over long periods of time. animal data embryofetal development studies conducted with clobetasol propionate in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and malformations at all dose levels tested down to 0.03 mg/kg. malformations seen included cleft palate and skeletal abnormalities. in an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg. malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities. risk summary there is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clobetasol propionate foam, 0.05% and any potential adverse effects on the breastfed infant from clobetasol propionate foam, 0.05% or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use clobetasol propionate foam, 0.05% on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply clobetasol propionate foam, 0.05% directly to the nipple and areola to avoid direct infant exposure. safety and effectiveness of clobetasol propionate foam, 0.05% in patients younger than 12 years of age have not been established; therefore, use in children younger than 12 years is not recommended. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity when they are treated with topical drugs. they are, therefore, also at greater risk of adrenal insufficiency upon the use of topical corticosteroids. rare systemic toxicities such as cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients especially those with prolonged exposure to large doses of high potency topical corticosteroids. local adverse reactions including striae have also been reported with use of topical corticosteroids in pediatric patients. avoid use of clobetasol propionate foam, 0.05% in the treatment of diaper dermatitis. clinical studies of clobetasol propionate foam, 0.05% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range. clobetasol propionate foam, 0.05% important: clobetasol propionate foam, 0.05% is for use on the skin only. do not get clobetasol propionate foam, 0.05% in your eyes, mouth, or vagina. how to apply clobetasol propionate foam, 0.05%: step 1: remove the cap and save for further use. figure a step 2: before applying clobetasol propionate foam, 0.05% for the first time, break the tiny plastic piece at the base of the can’s rim by gently pushing back (away from the piece) on the nozzle. (see figure a ) figure b step 3: turn the can upside down. push the button to dispense a small amount of clobetasol propionate foam, 0.05% into the cap of the can, or on your affected skin area. (see figure b ) this amount should be no more than 1 ½ capfuls, about the size of a golf ball. figure c figure d step 4: using your fingertips, gently massage a thin layer of clobetasol propionate foam, 0.05% into the affected areas until the foam disappears. (see figures c and d ) figure e step 5: if you are treating areas with hair, such as the scalp, move any hair away so that the foam can be applied directly to the affected areas. (see figure e ) keep the foam away from your eyes, as it will sting and may cause eye problems if there is frequent contact with your eyes. if the foam gets in your eyes, rinse them well with cold water right away. if the stinging continues, contact your healthcare provider right away. figure f step 6: wash your hands after applying clobetasol propionate foam, 0.05%. (see figure f ) this instructions for use has been approved by the u.s. food and drug administration.

ABD - İngilizce - NLM (National Library of Medicine)

golden state medical supply, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate gel, cream and ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate gel, cream and ointment are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.